Antiplatelet Agent

13 Drugs classified under this drug class

Antiplatelet Agent. Tirofiban HCl Monohydrate 0.05 mg/ml.
VIAL FOR INJECT: 1 x 12.5 mg/50 ml
(0.25 mg/ml).
INFUS. BAG: 1 x 12.5 mg/250 ml (0.05
mg/ml). Initial: 0.4 μg/kg/min of
diluted sol. by I.V. Then 0.1 μg/kg/min.
See lit.
In comb. with heparin in unstable
ang. or non-Q-wave M.I., prevent card.
ischem. events, acute coronary syndr.
(incl. medically managed and
undergoing PTCA or atherectomy). See
lit.

Antiplatelet Agent. Acetylsalicylic Acid 100 mg.
TABS: 30, 90. 1 tab. dly.
Prim. prevent. coron. heart dis. in pts at
incr. risk, second. prevent. thrombot.
cerebrovasc./cardiovasc. dis.

Antiplatelet Agent. Ticagrelor 60 mg, 90 mg.
F.C. TABS: 56. Pts. taking Ticagrelor should also take ASA dly., unless specific. contraind.
Follow. an init. dose of ASA, Ticagrelor should be used with a mainten. dose of ASA of 75-150 mg.
Acute coron. syndr.: Ticagrelor tmt. should be initi. with a single 180 mg load. dose (2 tabs. of 90 mg) and then contin. at 90 mg ×2/d.
Tmt. with Ticagrelor 90 mg ×2/d is recomm. for up to 12 mnths. in ACS pts. unless discont. is clinic. indic.
Ticagrelor 60 mg ×2/d dly. is the recomm. dose when an extend. tmt. is requir. for pts. with a hist. of MI of at least 1 year and a high risk of an atherothrombot. event. Tmt. may be started without interrupt. as contin. ther. after the init. 1 -year tmt. with Ticagrelor 90 mg or other adenosine diphosphate (ADP) recept. inhib. ther. in ACS pts. with a high risk of an atherothrombot. event. Tmt. can also be init. up to 2 yrs. from the MI, or within 1 year after stop. prev. ADP recept. inhibit. tmt.
In pts. with ACS, premat. discont. with any antiplat. ther., includ. Ticagrelor, could result in an incr. risk of cardiovasc. death, or MI due to the pt’s. underlying dis. Therefore, premature discont. of tmt. should be avoided. See lit.
Indic. co-admin. with ASA, is for the preven.  of atherothrombot. events in adult pts. with - acute coron. syndr. (ACS) or - a hist. of MI and a high risk of develop. an atherothrombot.
Limitations of use: 90 mg ×2/d during the 1^st year after an ACS event follow. by 60 mg ×2/d for addit. 2 yrs.
C/I: Hypersens. Active pathology. bleed. History of intracran. haemorr. Severe hep. impair. Co-admin. with strong CYP3A4 inhib. (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir).

Antiplatelet Agent. Acetylsalicylic Acid 100 mg.
E.C. TABS (Calendar): 28. 1 tab. dly.
Inhibit. platelet aggregat.
C/I: Known hypersens., digesti. syst.
bleed./ulc., gout.

Antiplatelet Agent. Clopidogrel (as hydrogen sulphate) 75 mg.
TABS: 30. 75 mg dly as single dose
with/out food. Non-ST seg. elevat.
acute coronary syndr. (unstable
angina/non-Q-wave MI). Initial: 300
mg load. dose, cont. with 75 mg 1 x dly
(with ASA 75-325 mg dly - optimal:
100 mg dly). Max benefit within 3
mths. but can cont. for up to 12 mths.
ST seg. elevat. acute MI: 75 mg 1 x dly.
Load dose (in comb. with ASA with/
without thrombolyts.): Pts. over 75 yrs:
Comb. ther. as soon as possible aft.
onset sympts. Cont. for at least 4 wks.
Under 18 yrs: Safety/efficacy not
established.
Prevent. atherothromb: In pts. with M.I.
(from a few days until less than 35 days),
ischem. stroke (from 7 days-6 mths) or
estab. periph. art. dis. History recent M.I.,
recent stroke, estab. periph. art. dis, to
reduce rate of comb. endpoint new
ischem. stroke (fatal or not), new M.I. (fatal
or not), and other vasc. death. Acute
coron. syndr. [non-ST seg. elevat. acute
coron. syndr. (unstable angina/non-Qwave
M.I.) or ST seg. elevat. acute M.I. ] in
comb. with ASA in medically treat. pts.
eligible for thrombolyt. ther., percutan.
coron. intervent. (with/out stent) or CABG,
to decr. rate comb. endpoint CV death,
M.I., stroke or refract. ischem.

Antiplatelet Agent. Clopidogrel (as Besylate) 75 mg.
TABS: 30
75 mg dly as single dose with/without food. Non-ST seg. elevat. acute coronary syndr. (unstab. ang. non-Q-wave MI). Init.: 300 mg load. dose, cont. with 75 mg 1 x dly (with ASA 75-325 mg dly – optimal: 100 mg dly). Max benefit within 3 mths. but can cont. for up to 12 mths. ST seg. elevat. acute MI: 75 mg 1 x dly. Load dose (in comb. with ASA with/without thrombolyts.): Pts. over 75 yrs: Init. without load dose. Comb ther. as soon as possible aft. onset sympts. Cont. for at least 4 wks. Atrial fibrillat.: 75 mg 1 x dly with ASA (75-100 mg dly) Under 18 yrs: not indicated.  
Second. prevent. atherothromb: In adult. with M.I.(from a few days until less than 35 d.),.ischem. stroke (from 7 days-6 mths) or estab. periph. art. dis.
Adults with Acute coron. syndr. non-ST seg. elevat. acute coron. syndr. (unstable angina/non-Q-wave M.I.) includ. pts. undergoing stent placement foll. percutan. coron. intervent., in comb. with ASA. ST seg. elevat. acute MI, in comb. with ASA in medically treat. pts. eligible for thrombolyt. ther.
Prevent. atherothromb/thromboemb. events in atrial fibrillat: Adult. with atrial fibrillat. with at least one risk factor for vasc. events, and not suitable for tmt. with VKA, anti-thrombin or anti factor Xa, who have low bleed. risk. in combinat. with ASA for prevent. atherothrombotic/thromboemb. events, includ. stroke.
C/I: Hypersens., severe hep. impair., active path. bleed. as peptic ulc., intracran. hemorrhage. See lit.